Role of Inflammation in Carpal Tunnel Syndrome

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the role of inflammation in carpal tunnel syndrome (CTS) using a prospective cohort study design. The study will involve a sample of at least 50 individuals with CTS who will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The primary outcome measures include inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity. Data will be analyzed using regression analysis to determine the relationship between inflammation and CTS. The study is expected to provide information on the role of inflammation in CTS and inform the choice of drug and concentration for transdermal drug administration.

Official Title
-----------------
Role of Inflammation in Carpal Tunnel Syndrome: A Prospective Cohort Study

Conditions
-----------------
Carpal Tunnel Syndrome, Median Neuropathy, Carpal Tunnel

Intervention / Treatment
-----------------
* Diagnostic Test: Inflammatory markers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals aged 18 years or older Diagnosis of carpal tunnel syndrome based on clinical symptoms and nerve conduction studies Willingness and ability to provide informed consent to participate in the study Willingness and ability to comply with study procedures and follow-up visits Exclusion Criteria: Presence of other neurological conditions that may affect nerve function in the upper extremities Use of medications that may affect inflammation or carpal tunnel syndrome severity History of previous carpal tunnel release surgery on the affected wrist Inability to comply with study procedures or follow-up visits Pregnancy or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Individuals with carpal tunnel syndrome<br>This study will follow a group of individuals with carpal tunnel syndrome (CTS) according to Bland's grading scale (grades 1-3) to assess the role of inflammation in CTS. Participants will undergo clinical and biochemical evaluations to assess inflammatory markers and CTS severity. The study will follow participants over time to determine the relationship between inflammation and CTS, which can inform the choice of transdermal drug administration. | Diagnostic Test: Inflammatory markers<br>* Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The relationship between inflammatory markers and symptom severity of carpal tunnel syndrome (CTS). | interleukin-6, tumor necrosis factor-alpha using blood tests. Symptom severity will be assessed with standardized questionnaire the Boston Carpal Tunnel Questionnaire. | Changes of inflammatory markers and symptoms severity at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline | 
| The relationship between inflammatory markers and grip strength of patients with CTS. | interleukin-6, tumor necrosis factor-alpha using blood tests. functional status by grip strength using a dynamometer. | Changes of inflammatory markers and grip strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline | 
| The relationship between inflammatory markers and pinch strength of CTS patients. | interleukin-6, tumor necrosis factor-alpha using blood tests. pinch strength will be measured using a dynamometer | Changes of inflammatory markers and pinch strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline | 
| The relationship between inflammatory markers and nerve conduction study of patients with CTS | interleukin-6, tumor necrosis factor-alpha using blood tests. Nerve conduction study results (motor and sensory distal latency of median nerve and amplitude) will be used to determine CTS severity based on Bland's grading scale. | Changes of inflammatory markers and nerve conduction study at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline |